The Clorox Company (CLX) has flipped from a low-conviction bearish stance to a high-conviction bullish one after a blowout fiscal first-quarter earnings report on November 3, 2026. The stock surged 13.6% over five days, breaking above its 200-day average and now trades at $99.96, just below the round $100 level. The balance of evidence leans positive for the next 2–6 weeks, with the daily trend aligned with the weekly uptrend and the stock leading both the S&P 500 and its sector.
Why it matters
CLX reported adjusted EPS of $1.55, up 82% year-over-year and beating the $1.07 consensus, while revenue rose 33% to $1.91 billion, topping the $1.88 billion forecast, according to Benzinga. Organic sales grew 18%, though gross margin contracted 130 basis points to 40.4% due to higher commodity and manufacturing costs. The market rewarded the beat with a 13.6% five-day gain, but the move was not just about the numbers — it was about what the numbers meant for the thesis.
Before earnings, the stock was down 22% year-to-date, with the debate centered on the debt-funded GOJO (Purell) acquisition, an ERP transition, and input cost inflation, as Seeking Alpha noted on October 29. The dividend yield was around 6%, with a payout ratio of 83–88% implied by guidance, which was high but covered. The bear case, articulated by The Motley Fool on October 26, was that organic sales fell 8% in fiscal 2026 and the stock was near its 52-week low. The bull case, from Morningstar, was that CLX has a wide economic moat and trades below fair value.
The earnings report resolved the debate in favor of the bulls. The 18% organic sales growth showed the GOJO acquisition is not just adding revenue but also driving underlying demand. The stock's 5-day gain of 13.6% versus the S&P 500's -2.7% and XLP's 0.7% shows this was a stock-specific move, not a market or sector lift. The stock is now 12.9 percentage points ahead of its sector over five days, confirming that the market is re-rating CLX on its own merits.
Valuation remains a point of tension. The consensus analyst target is $97.75, with a low of $74 and a high of $154, and the stock trades 2.3% above the mean target, according to the data. The consensus rating is hold, which suggests the street is still catching up to the earnings beat. The stock's 50-day relative strength versus the S&P 500 is +18.6%, and versus XLP it is +7.6%, showing sustained outperformance that predates the earnings move.
What the evidence says
The long-term thesis is intact and strengthening. The stock is above its 40-week average, and the daily trend runs with the weekly uptrend — the trend alignment is now aligned, a shift from the pullback phase noted in the previous assessment. The stock is above its 200-day average at $99.41, and the 50-day average at $87.71 is well below price, confirming the uptrend. The 52-week range shows the stock is 21.4% below its high of $127.16 but 24.3% above its low of $80.41, indicating room to run if the breakout completes.
For the next 2–6 weeks, the balance of evidence leans positive with high conviction, supported by 3 of 4 conviction points. The daily trend is aligned with the weekly uptrend, the stock leads the S&P 500 by 18.6% over 50 days, and it leads XLP by 7.6% over the same period. The previous assessment on November 3, 2026, was bearish with low conviction, expecting a weekly close above the 200-day average at $99.58 to invalidate that view. That level was crossed on November 6, and the stance has changed to bullish. The strongest case against the bullish reading is the RSI at 77, which is overbought, and the stock's 5-day gain of 13.6% may invite profit-taking. However, the trend is strong, and overbought conditions can persist in uptrends. The volume on the breakout day was below the 20-day average by 12.5%, which is a minor concern, but the price action has been decisive.
Levels that matter
The structure holds above the 200-day average at $99.41. A daily close below that level would be the first crack, and a weekly close below $98.75 — a swing zone — would end the trend. The stock closed at $99.96 on November 6, just above the 200-day average, so the immediate support is thin. The 50-day average at $87.71 is the next major support, but a drop to that level would represent a 12% decline from current prices.
The breakout level is a daily close above $100.00 on volume above the 20-day average. From there, the first target is $100.57, a swing zone, which offers only 0.4 to 1 reward-to-risk against a stop at $98.59. The second target is $108.68, another swing zone, which offers 6.2 to 1 reward-to-risk. The math meets the 3-to-1 threshold for the second target, making the breakout worth the risk. The stop at $98.59 is based on the 200-day average minus a quarter of the ATR, providing a logical invalidation point. If the stock fails to break above $100, the range between $99.41 and $100.00 will define the near-term action.
What would change the picture
A weekly close below $98.75 would change the picture, as it would break the swing zone and signal that the earnings-driven rally has failed. The other non-price fact that would change the picture is a deterioration in the consumer spending outlook, as highlighted by CEO Linda Rendle's comments on November 3 about consumers seeking value and delaying purchases, reported by TheStreet. If input-cost inflation rises further — the company raised its estimate to $240 million, up $40 million from prior guidance — margins could compress and undermine the earnings beat.
What to watch
- Next earnings: February 2, 2027. The key number is gross margin, which contracted 130 basis points in Q1; a further contraction would test the bullish thesis.
- Sector events: The surface disinfectant market is projected to grow at 7.4% CAGR to $7.5 billion by 2031, per PR Newswire, which supports the growth narrative for CLX's cleaning products.
- Valuation: The stock trades 2.3% above the consensus target of $97.75, with a wide analyst range of $74 to $154, suggesting the market is still debating the fair value post-earnings.